JP2020524143A5 - - Google Patents

Download PDF

Info

Publication number
JP2020524143A5
JP2020524143A5 JP2019569758A JP2019569758A JP2020524143A5 JP 2020524143 A5 JP2020524143 A5 JP 2020524143A5 JP 2019569758 A JP2019569758 A JP 2019569758A JP 2019569758 A JP2019569758 A JP 2019569758A JP 2020524143 A5 JP2020524143 A5 JP 2020524143A5
Authority
JP
Japan
Prior art keywords
composition according
bioactive agent
lipid
oil
sorbitan ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019569758A
Other languages
English (en)
Japanese (ja)
Other versions
JP7866358B2 (ja
JP2020524143A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037783 external-priority patent/WO2018232257A1/en
Publication of JP2020524143A publication Critical patent/JP2020524143A/ja
Publication of JP2020524143A5 publication Critical patent/JP2020524143A5/ja
Priority to JP2024000126A priority Critical patent/JP2024029173A/ja
Application granted granted Critical
Publication of JP7866358B2 publication Critical patent/JP7866358B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019569758A 2017-06-15 2018-06-15 ナノ構造脂質担体、安定エマルジョン、およびその使用 Active JP7866358B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024000126A JP2024029173A (ja) 2017-06-15 2024-01-04 ナノ構造脂質担体、安定エマルジョン、およびその使用

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US201762520204P 2017-06-15 2017-06-15
US62/520,204 2017-06-15
US201762540973P 2017-08-03 2017-08-03
US62/540,973 2017-08-03
US201762556291P 2017-09-08 2017-09-08
US62/556,291 2017-09-08
US201762563544P 2017-09-26 2017-09-26
US62/563,544 2017-09-26
US201762582859P 2017-11-07 2017-11-07
US62/582,859 2017-11-07
US201862622748P 2018-01-26 2018-01-26
US201862622755P 2018-01-26 2018-01-26
US62/622,748 2018-01-26
US62/622,755 2018-01-26
US201862669262P 2018-05-09 2018-05-09
US62/669,262 2018-05-09
US201862677336P 2018-05-29 2018-05-29
US62/677,336 2018-05-29
US201862680454P 2018-06-04 2018-06-04
US62/680,454 2018-06-04
PCT/US2018/037783 WO2018232257A1 (en) 2017-06-15 2018-06-15 Nanostructured lipid carriers and stable emulsions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024000126A Division JP2024029173A (ja) 2017-06-15 2024-01-04 ナノ構造脂質担体、安定エマルジョン、およびその使用

Publications (3)

Publication Number Publication Date
JP2020524143A JP2020524143A (ja) 2020-08-13
JP2020524143A5 true JP2020524143A5 (cg-RX-API-DMAC7.html) 2021-07-29
JP7866358B2 JP7866358B2 (ja) 2026-05-27

Family

ID=62948328

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019569758A Active JP7866358B2 (ja) 2017-06-15 2018-06-15 ナノ構造脂質担体、安定エマルジョン、およびその使用
JP2024000126A Withdrawn JP2024029173A (ja) 2017-06-15 2024-01-04 ナノ構造脂質担体、安定エマルジョン、およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024000126A Withdrawn JP2024029173A (ja) 2017-06-15 2024-01-04 ナノ構造脂質担体、安定エマルジョン、およびその使用

Country Status (13)

Country Link
US (3) US11141377B2 (cg-RX-API-DMAC7.html)
EP (1) EP3638207B1 (cg-RX-API-DMAC7.html)
JP (2) JP7866358B2 (cg-RX-API-DMAC7.html)
KR (2) KR102673794B1 (cg-RX-API-DMAC7.html)
CN (1) CN111315362A (cg-RX-API-DMAC7.html)
AU (1) AU2018285694B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019026615B1 (cg-RX-API-DMAC7.html)
CA (1) CA3067224A1 (cg-RX-API-DMAC7.html)
ES (1) ES3003260T3 (cg-RX-API-DMAC7.html)
IL (1) IL271384B2 (cg-RX-API-DMAC7.html)
MX (4) MX2019015076A (cg-RX-API-DMAC7.html)
WO (1) WO2018232257A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201908207B (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018285694B2 (en) 2017-06-15 2025-04-10 Access To Advanced Health Institute Nanostructured lipid carriers and stable emulsions and uses thereof
US12180370B2 (en) 2019-01-15 2024-12-31 Nant Holdings Ip, Llc Aragonite uses
US12514796B2 (en) 2019-01-15 2026-01-06 Nant Holdings Ip, Llc Aragonite compositions, methods, and uses thereof
US20220339116A1 (en) * 2019-04-03 2022-10-27 The Johns Hopkins University Lipid nanoparticles as oral vehicles of immunotherapy
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
WO2021194672A1 (en) 2020-03-23 2021-09-30 Hdt Bio Corp. Compositions and methods for delivery of rna
EP4058581A1 (en) * 2019-11-15 2022-09-21 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
AU2021226149A1 (en) * 2020-02-26 2022-10-06 Capcium Inc. Nanostructure lipid carrier delivery system, composition, and methods
CN111494619B (zh) * 2020-04-26 2022-03-18 南京农业大学 一种基于角鲨烯的阳离子纳米结构脂质载体免疫佐剂的制备方法
US20230310323A1 (en) 2020-09-04 2023-10-05 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
WO2022051024A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Genetically-adjuvanted rna vaccines
JP2024501949A (ja) * 2020-12-23 2024-01-17 アクセス ツー アドバンスト ヘルス インスティチュート ソラネソールワクチンアジュバント及びその調製方法
US20240252620A1 (en) * 2021-05-28 2024-08-01 The Regents Of The University Of Michigan Combined agonist adjuvant for coronavirus vaccine
IN202121031414A (cg-RX-API-DMAC7.html) * 2021-07-13 2023-01-13
US20240327492A1 (en) 2021-07-29 2024-10-03 Nantcell, Inc. Modified T Cell Receptors For The Prevention And Treatment Of Viral Infections And Cancer
KR102681030B1 (ko) * 2021-08-02 2024-07-02 한국화학연구원 올리고뉴클레오타이드가 봉입된 나노입자, 이의 제조방법 및 이를 포함하는 약학적 제제
US20250134991A1 (en) * 2021-08-20 2025-05-01 Thomas Jefferson University Monophosphoryl lipid adjuvant (mpla) compositions, vaccine compositions thereof, and methods of preparing and using the same
AU2022352486A1 (en) * 2021-09-22 2024-04-11 Hdt Bio Corp. Dried nanoparticle compositions
JP2024535352A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション Sars-cov-2 rnaワクチン組成物および使用方法
CA3232658A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Rna vaccines against infectious diseases
CA3232562A1 (en) * 2021-09-22 2023-03-30 Malcolm S. Duthie Nucleic acid sensor agonist compositions and uses thereof
AU2022358446A1 (en) * 2021-09-22 2024-04-18 Hdt Bio Corp. Compositions and methods for enhanced protein production
WO2023049636A2 (en) * 2021-09-22 2023-03-30 Hdt Bio Corp. Cancer therapy compositions and uses thereof
EP4460326A4 (en) * 2022-01-07 2026-03-11 Hdt Bio Corp COMPOSITIONS AND METHODS ASSOCIATED WITH MULTIVALENT IMMUNE RESPONSES
WO2023228116A1 (en) 2022-05-24 2023-11-30 Access To Advanced Health Institute Intranasal administration of thermostable rna vaccines
EP4547258A4 (en) * 2022-06-28 2026-08-05 Transcode Therapeutics Inc Matrix-Directed Rig-I Agonitor Nanoparticles and Precursor Compositions and Their Uses in Cancer Therapy
KR102901149B1 (ko) * 2022-09-05 2025-12-17 주식회사 차백신연구소 에멀전 제형의 면역증강제 조성물 및 이의 제조 방법
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
CN116159145B (zh) * 2023-01-31 2025-04-22 四川大学 含七叶皂苷和/或其盐化合物的转染复合物在促转染的应用
CN116392586B (zh) * 2023-04-12 2025-06-24 江苏中慧元通生物科技股份有限公司 一种纳米乳佐剂
EP4694920A1 (en) * 2023-04-14 2026-02-18 BioNTech SE Rna for preventing or treating tuberculosis
EP4734962A1 (en) * 2023-06-29 2026-05-06 RIGImmune Inc. Novel formulations
WO2025244961A1 (en) * 2024-05-22 2025-11-27 Merck Sharp & Dohme Llc Processes for making stable nanoemulsion adjuvants
WO2026096272A1 (en) * 2024-10-30 2026-05-07 Virginia Commonwealth University Equine lyme disease vaccines and methods
ES3069647A1 (es) * 2024-12-09 2026-06-09 Consejo Superior Investigacion Transportadores lipídicos nanoestructurados para inhibir la formación de biopelículas bacterianas
CN121944103B (zh) * 2026-04-03 2026-07-03 华诺泰生物医药科技(成都)有限公司 一种含角鲨烯的水包油佐剂及其制备方法与应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
EP0304578B1 (en) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide comprising hepatitis B surface antigen
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
JP3237842B2 (ja) 1988-12-16 2001-12-10 オランダ国 ニューモリシンミュータント及びそれから製造されたニューモコッカルワクチン
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
DK0414374T3 (da) 1989-07-25 1998-03-09 Smithkline Beecham Biolog Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
EP1359156B1 (en) 1991-07-19 2007-03-07 University of Queensland Vaccine against Human Papillomavirus (Type 18)
JP3954643B2 (ja) 1991-11-16 2007-08-08 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム マラリア原虫由来のCSおよびHBsAG間のハイブリッド蛋白質
PT647140E (pt) 1992-06-25 2007-12-27 Univ Georgetown Vacinas de papilomavírus
US5786148A (en) 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
DE69434383T2 (de) 1993-03-09 2005-11-24 The University Of Rochester Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
EP1728800A1 (de) 1994-10-07 2006-12-06 Loyola University Of Chicago Papillomavirusähnliche Partikel, Fusionsproteine sowie Verfahren zu deren Herstellung
AU4727296A (en) 1995-02-24 1996-09-11 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
ES2301178T3 (es) 1996-04-05 2008-06-16 Novartis Vaccines & Diagnostic Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular.
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5955306A (en) 1996-09-17 1999-09-21 Millenium Pharmaceuticals, Inc. Genes encoding proteins that interact with the tub protein
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
CA2281954A1 (en) 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
AU740956B2 (en) 1997-07-21 2001-11-15 Baxter Healthcare Sa Modified immunogenic pneumolysin compositions as vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
KR100760221B1 (ko) 1997-11-28 2007-10-30 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
BR9907691B1 (pt) 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
BR9909472A (pt) 1998-04-07 2001-09-11 Corixa Corp Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica
JP2002511266A (ja) 1998-04-15 2002-04-16 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 腫瘍関連核酸及びその使用
TR200100916T2 (cg-RX-API-DMAC7.html) 1998-07-14 2002-06-21 Corixa@@Corporation
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
US6533949B1 (en) 2000-08-28 2003-03-18 Nanopass Ltd. Microneedle structure and production method therefor
US20030138453A1 (en) 2000-09-28 2003-07-24 O'hagan Derek Microparticles for delivery of heterologous nucleic acids
WO2004058166A2 (en) 2002-12-23 2004-07-15 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
US7998119B2 (en) 2003-11-18 2011-08-16 Nano Pass Technologies Ltd. System and method for delivering fluid into flexible biological barrier
JP5331340B2 (ja) 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2008124647A2 (en) 2007-04-04 2008-10-16 Infectious Disease Research Institute Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
EP2200639B1 (en) * 2007-09-24 2016-03-30 Government of the USA, as Represented by the Secretary, Department of Health and Human Services Immunostimulatory combinations of tlr3 ligands with tlr2 and tlr9 agonists and methods of use
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
US9636410B2 (en) 2011-07-06 2017-05-02 Glaxosmithkline Biologicals Sa Cationic oil-in-water emulsions
RU2014104090A (ru) * 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
US10322089B2 (en) * 2012-03-14 2019-06-18 The Board Of Trustees Of The Leland Stanford Junior University Nanoparticles, nanoparticle delivery methods, and systems of delivery
US8809388B2 (en) * 2012-11-06 2014-08-19 Brandeis University Vegetable oil composition containing palm mid-fraction fat and method of reducing plasma cholesterol
AU2014204826A1 (en) * 2013-01-10 2015-07-09 Seqirus UK Limited Influenza virus immunogenic compositions and uses thereof
CN115837014A (zh) * 2016-05-18 2023-03-24 摩登纳特斯有限公司 编码松弛素的多核苷酸
AU2018285694B2 (en) 2017-06-15 2025-04-10 Access To Advanced Health Institute Nanostructured lipid carriers and stable emulsions and uses thereof

Similar Documents

Publication Publication Date Title
Chatzikleanthous et al. Lipid-based nanoparticles for delivery of vaccine adjuvants and antigens: toward multicomponent vaccines
JP7333563B2 (ja) 脂質ナノ粒子
JP6505912B2 (ja) 改良されたアミノ脂質および核酸の送達方法
Kim et al. Nanotechnology and vaccine development
Davidsen et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6, 6′-dibehenate)—a novel adjuvant inducing both strong CMI and antibody responses
JP2013531680A5 (cg-RX-API-DMAC7.html)
DK2729127T3 (en) METHODS FOR LIPOSOMES PREPARATION
RU2014104092A (ru) Эмульсии типа "масло в воде", которые содержат нуклеиновые кислоты
US20170049702A1 (en) Method to Enhance an Immune Response of Nucleic Acid Vaccination
JP2023518976A (ja) Rnaを送達するための組成物および方法
US20110177156A1 (en) Sterol-Modified Amphiphilic Lipids
JP7821776B2 (ja) 効率的な核酸送達のための担体
Paecharoenchai et al. Structure relationship of cationic lipids on gene transfection mediated by cationic liposomes
EP3147277B1 (en) Lipid membrane structure for sirna intracellular delivery
CN1980638B (zh) 用糖脂稳定基于脂质的佐剂制剂的组合物和方法
Wang et al. Advances in the study of LNPs for mRNA delivery and clinical applications
JP2024535351A5 (cg-RX-API-DMAC7.html)
Perrie et al. Surfactant vesicle-mediated delivery of DNA vaccines via the subcutaneous route
Ahmad et al. Liposomes and niosomes for targeted drug and gene delivery systems
Nie et al. Synthetic nanomaterials for spleen-specific mRNA delivery
Porte et al. A molecular view of lipid nanoparticles: insights into their morphology and structural plasticity
WO2024209013A1 (en) Lipid nanoparticle compositions
Vaquero et al. Incorporation of monophosphoryl lipid A and CpG-oligodeoxynucleotides into lipid nanoparticles activates toll-like receptor signaling pathways while maintaining antigen expression for mRNA-based vaccinations
Wölk et al. Investigation of binary lipid mixtures of a three-chain cationic lipid with phospholipids suitable for gene delivery
JP5390059B2 (ja) 無菌ポリヌクレオチド系薬剤の製造方法